Neuropsychiatric problems in patients with multiple sclerosis

Psychiatric Annals

Volumn 32, Issue 2, 2002, Pages 128-132

  Schiffer, Randolph B ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; ANTIDEPRESSANT AGENT; AZATHIOPRINE; CARBAMAZEPINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DESIPRAMINE; LITHIUM; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID;

BEHAVIOR DISORDER; BIPOLAR DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; DIAGNOSTIC PROCEDURE; DISABILITY; EMOTIONAL DISORDER; EPIDEMIOLOGICAL DATA; EUPHORIA; FATIGUE; HUMAN; MAJOR DEPRESSION; MOOD DISORDER; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; NEUROPSYCHIATRY; PATHOLOGICAL CRYING; PATHOLOGICAL LAUGHTER; PATHOPHYSIOLOGY; PSYCHOSIS; REVIEW; SEXUAL DYSFUNCTION;

EID: 0036108974     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-20020201-10     Document Type: Review

References (18)

1. Nodder D, Chappell B, Bates D, et al. Multiple sclerosis: care needs for 2000 and beyond. J R Soc Med. 2000;93:219-224.
2. Lublin FD, Reingold SC. Neurology. 1996;46:907-911.
3. Cannella B, Raine CS, Lucas K, Hohlfeld R. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol. 1995;37:424-435.
4. Hernan MA, Olek MJ, Ascherio A. Geographic variation of MS incidence in two prospective studies of US women. Neurology. 1999;53:1711-1718.
5. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227-231.
6. Schiffer RB, Giang DW, Mushlin A, et al. Perils and pitfalls of MR scanning in the diagnosis of multiple sclerosis. J Neuroimaging. 1993;3:81-88.
7. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis, I: frequency, patterns, and prediction. Neurology. 1991;41:685-691.
8. Joffe RT, Lippert GP, Gray TA, Sawa G, Horvath Z. Mood disorder and multiple sclerosis. Arch Neurol. 1987;44:376-378.
9. Foley FW, Miller AH, Traugott U, et al. Psychoimmunological dysregulation in multiple sclerosis. Psychosomatics. 1988;29:398-403.
10. Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BG, Burks JS. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology. 1996;46:12-18.
11. Schiffer RB, Wineman NM, Weitkamp LR. Association between bipolar affective disorder and multiple sclerosis. Am J Psychiatry. 1986;143:94-95.
12. Mattson D, Petrie M, Srivastava DK, McDermott M: Multiple sclerosis. Sexual dysfunction and its response to medications. Arch Neurology. 1995;52:862-868.
13. Feinstein A, du BG, Ron MA. Psychotic illness in multiple sclerosis. A clinical and magnetic resonance imaging study. Br J Psychiatry. 1992;161:680-685.
14. Weinstein A, Schiffer RB, Schwid SR, et al. Neuropsychological status in multiple sclerosis after treatment with glatiramer. Arch Neurology. 1999;56:319-324.
15. Pliskin NH, Hamer DP, Goldstein DS, et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon B-1b. Neurology. 1996;47:1463-1476.
16. Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry. 1990;147:1493-1497.
17. Schiffer RB, Herndon RM, Rudick RA. Treatment of pathologic laughing and weeping with amitriptyline. N Engl J Med. 1985;312:1480-1482.
18. Krupp LB, Coyle PK, Doscher C, et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology. 1995;45:1956-1961.